(c)
fluticasone propionate, when intended for nasal administration, other than by aerosol,
in the short-term (less than 6 months) prophylaxis and treatment of symptoms of allergic rhinitis (hay
fever) in adults and children over 12, where the maximum daily dose per nostril is 100 micrograms and
the pack size is limited to 120 doses. (S2, S4)
Cyclandalate.
Cyclopentolate; ophthalmic preparations thereof. (S2)
Debrisoquine.
Delapril.
Dichlorphenamide.
Diclofenac, except when intended for application to the skin, (S1) and except when intended for the
emergency treatment of acute gout attacks and except when intended for the treatment of post
traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S2)
Diflunisal.
Diftalone.
Digitalis; its glycosides and other active principles thereof, unless diluted below one unit (BP) in each 2,0
grams.
Dihydroergocristine.
Dilevalol.
Diltiazem.
Dimercaprol, when intended for injection.
Dipivefrin.
Dipyridamole.
Dipyrocetyl.
Disulfiram.
Dithranol.
Domase alfa (rh DNase).
Dorzolamide.
Doxazosin.
Eltenac.
Enalapril.
Endralazine.
Eprosartan.
Escin (aescin), except preparations and mixtures thereof intended for application to the skin and
containing 1,0 percent or less of escin. (S1)
Esculin, when intended for oral use.
Esmolol.
Ethacrynic acid.
Ethambutol.
Ethionamide, when intended for oral use.
Ethosuximide.
Etisazol.
Etodolac.
Etodolic acid.
Felbamate.
Felodipine.
Fenbufen.
Fenclofenac.
Fendiline.
Fenofibrate.
Fenoprofen, except when intended for the emergency treatment of acute gout attacks and when
intended for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a
maximum period of 5 days. (S2)
Fenoterol, when contained in respirator solutions. (S2, S4)
Fentiazac.
Floctafenine.
Flufenamic acid, except preparations and mixtures intended for application to the skin. (S1)
Flunixin.
Flurbiprofen, except—
(a)
when intended for ophthalmic use; (S4)
(b)
when intended for application to the skin, including application by transdermal patch,
the indications are for use by adults and children 12 years and older and the treatment period is limited
to 4 weeks; (S1)
(c)
when supplied by a pharmacist to a patient and intended for the treatment of posttraumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S2)
Fosinopril.
Furosemide.
Gabapentin.